search
Back to results

Imaging Biomarkers of Pancreatic Function and Disease

Primary Purpose

Pancreatitis, Diabetes Mellitus

Status
Enrolling by invitation
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Research MRI without administration of intravenous secretin
Research MRI with administration of intravenous secretin
Genetic Sequencing
Blood Tests
Stool Tests
Survey Completion
Endoscopic pancreatic function tests (ePFTs)
Secretin
Sponsored by
Children's Hospital Medical Center, Cincinnati
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Pancreatitis focused on measuring MRI

Eligibility Criteria

5 Years - 21 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Aim 1- Patient Group: Inclusion Criteria: Age 5 to <21 years Scheduled for clinically-indicated gastrointestinal endoscopy Clinical diagnosis or suspicion of exocrine pancreatic insufficiency Exclusion Criteria: Complete fatty replacement of pancreas on prior imaging Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Allergy to secretin Pregnancy Control Group: Inclusion Criteria: Age 5 to <21 years Scheduled for clinically-indicated gastrointestinal endoscopy Exclusion Criteria: Sweat chloride >60 mmol/L Clinical diagnosis of gastrointestinal pathology Clinical diagnosis or history of pancreatic disease Complete fatty replacement of pancreas on prior imaging Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Allergy to secretin Pregnancy Aim 2- Acute Pancreatitis Group: Inclusion Criteria: Age 5 to <21 years Clinically documented episode of acute pancreatitis Exclusion Criteria: More than one episode of acute pancreatitis Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Pregnancy Acute Recurrent Pancreatitis Group: Inclusion Criteria: Age 5 to <21 years Clinical diagnosis of acute recurrent pancreatitis Exclusion Criteria: Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Pregnancy Pancreatitis-Related Diabetes Group: Inclusion Criteria: Age 5 to <21 years Clinical diagnosis of pancreatitis-related diabetes Exclusion Criteria: Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Pregnancy Aim 3- Control Group: Inclusion Criteria: • Age 5 to <21 years Exclusion Criteria: Sweat chloride >60 mmol/L Clinical diagnosis of gastrointestinal pathology Clinical diagnosis or history of pancreatic disease, including acute pancreatitis Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Allergy to secretin Pregnancy Acute Pancreatitis Group: Inclusion Criteria: Age 5 to <21 years Clinically documented episode of acute pancreatitis Exclusion Criteria: More than one episode of acute pancreatitis Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Allergy to secretin Pregnancy Acute Recurrent Pancreatitis Group: Inclusion Criteria: Age 5 to <21 years Clinical diagnosis of acute recurrent pancreatitis with no evidence of CP or EPI Exclusion Criteria: Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Allergy to secretin Pregnancy Chronic Pancreatitis Group: Inclusion Criteria: Age 5 to <21 years Clinical diagnosis of chronic pancreatitis Exclusion Criteria: Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Allergy to secretin Pregnancy Aim 4- Inclusion Criteria: Age 5 to <21 years Completed research MRI under Aims 1 or 3 of this study Exclusion Criteria: Failed/unable to complete first research MRI under Aims 1 or 3 Episode of acute pancreatitis since first research MRI Current acute pancreatitis Any gastrointestinal surgery or pancreas intervention (e.g. ERCP) since first research MRI Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Allergy to secretin Pregnancy Aim 5- Inclusion Criteria: • MRI performed at CCHMC Exclusion Criteria: Severe image artifact compromising image quality (judgement of study team) Age >21 years

Sites / Locations

  • Cincinnati Children's Hospital Medical Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

No Intervention

Arm Label

Imaging markers of exocrine and endocrine insufficiency

Imaging markers of diabetes and prediction of progression to diabetes

Imaging stratification of stages of pancreatitis

Imaging reproducibility

Automated or semi-automated image analysis

Arm Description

We will prospectively enroll 85 participants; 40 with known or suspected EPI and 45 controls (no known organic gastrointestinal pathology and no history of pancreatic disease) in this aim. Participants will be undergoing clinically-indicated endoscopy and will have endoscopic pancreatic function tests (ePFTs) collected for research during the clinically-indicated endoscopy examination. A research blood draw and a research stool collection will also be collected from all participants. Participants will undergo a research MRI examination with administration of intravenous secretin within 2 weeks of their clinical endoscopy but no sooner than 2 hours before or after endoscopy.

We will prospectively enroll 30 participants; 10 with a single episode of acute pancreatitis, 10 with acute recurrent pancreatitis, and 10 with pancreatitis-related diabetes in this aim. Participants will undergo a research MRI examination. Participants will also undergo a research blood draw for laboratory analysis and to enable gene sequencing for gene mutations associated with heritable pancreatitis. We will assess the association between identified gene variants and the presence of diabetes and will construct models based on identified variants to predict progression to diabetes.

We will prospectively enroll 60 participants; 15 healthy controls, 15 participants with a single episode of acute pancreatitis, 15 participants with acute recurrent pancreatitis, and 15 participants with chronic pancreatitis. A research blood draw and a research stool collection will be collected from all participants. Participants will undergo a research MRI examination with administration of intravenous secretin.

We will prospectively enroll up to 20 participants enrolled in Aims 1 or 3 (up to 5 controls and 15 patients with pancreatic disease) to undergo repeat research MRI imaging between 24 hours and 14 days after their first research MRI. Participants will undergo a research MRI examination with administration of intravenous secretin, identical to the research MRI performed under Aims 1 or 3. MRI images will be quantitatively analyzed and agreement between the two MRI examinations (1st and repeat MRI) will be assessed.

We will use images prospectively collected under Aims 1-3, as well as existing images that had been obtained for clinical care of children with pancreatitis at CCHMC to develop and optimize image processing pipelines for MRI images. Performance of these pipelines will be benchmarked against manual segmentation performed by multiple observers.

Outcomes

Primary Outcome Measures

Pancreas volume as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).
2 x 2 table analyses of pancreas volume (categorized as normal vs. abnormal) vs. exocrine function (categorized as normal vs. abnormal)
Pancreas volume as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).
2 x 2 table analyses of pancreas volume (categorized as normal vs. abnormal) vs. endocrine function (categorized as normal vs. abnormal)
Pancreas T1 signal as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).
2 x 2 table analyses of pancreas T1 signal (categorized as normal vs. abnormal) vs. exocrine function (categorized as normal vs. abnormal)
Pancreas T1 signal as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).
2 x 2 table analyses of pancreas T1 signal intensity (categorized as normal vs. abnormal) vs. endocrine function (categorized as normal vs. abnormal)
Pancreas secreted fluid volume as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).
2 x 2 table analyses of pancreas secreted fluid volume (categorized as normal vs. abnormal) vs. exocrine function (categorized as normal vs. abnormal)
Pancreas secreted fluid volume as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).
2 x 2 table analyses of pancreas secreted fluid volume (categorized as normal vs. abnormal) vs. endocrine function (categorized as normal vs. abnormal)
Frequency of genetic mutations in patients progressing to diabetes vs. those not
Frequency of genetic mutations in each study group will be compared using 2x2 tables to identify mutations associated with development of diabetes

Secondary Outcome Measures

Full Information

First Posted
November 22, 2022
Last Updated
January 19, 2023
Sponsor
Children's Hospital Medical Center, Cincinnati
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT05659147
Brief Title
Imaging Biomarkers of Pancreatic Function and Disease
Official Title
Imaging Biomarkers of Pancreatic Function and Disease
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
January 18, 2023 (Actual)
Primary Completion Date
December 2025 (Anticipated)
Study Completion Date
December 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Children's Hospital Medical Center, Cincinnati
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study seeks to understand the performance of MRI to characterize pancreatitis and predict chronic complications (endocrine and exocrine) of pancreatitis. Through multiple aims, the investigators will benchmark MRI against relevant reference standards (e.g. endoscopic pancreatic function tests, laboratory data). The investigators will also characterize repeatability of the imaging findings and will work to develop methods to simplify and automate analysis of the MRI images. Research interventions depend on the Aim(s) participants enroll in but include: endoscopic pancreatic function testing (added on to clinically indicated upper GI endoscopy), blood tests, stool tests, gene sequencing, and survey completion. All participants will undergo research MRI examinations, a subset of which will include administration of intravenous secretin.
Detailed Description
Pancreatitis can be acute [AP], acute recurrent [ARP] (defined as two discrete attacks with interval resolution), or chronic [CP]. Adult studies show that up to 40% of patients develop abnormal glucose metabolism after a single attack of AP, with a 2.5x increased risk of diabetes. CP is defined, in part, by the presence of established endocrine (diabetes) or exocrine pancreatic insufficiency [EPI]. Currently, it is not possible to non-invasively diagnose or predict development of pancreatitis-related endocrine or exocrine insufficiency. The investigator's data has shown that CFTR gene variants play a significant role in progression to diabetes post first attack AP. Existing literature suggests that imaging findings such as decreased pancreas volume are associated with diabetes, but this has not been systematically studied in children. EPI, defined as insufficient secretion of digestive enzymes and fluid by the pancreas, can have significant effects in childhood including malnutrition, osteoporosis, and growth failure. If diagnosed early, EPI can be treated with pancreatic enzyme replacement, improving nutrition and stabilizing growth. Unfortunately, diagnosing EPI early and accurately is a challenge in children and it is currently not possible to predict progression to CP or development of EPI. Magnetic resonance imaging (MRI) is a powerful, non-invasive technique, capable of characterizing pancreatic disease. Quantitative non-contrast MRI techniques are attractive as potential markers of pancreatic disease but they have not been validated for diagnosis or prediction of diabetes or EPI in children and they have not been explored for staging of pediatric pancreatitis. The overall goals of this study are to: Define associations between non-invasive, quantitative MRI measures and established measures of pancreas health and function including diabetes and EPI in children Identify clinical, genetic and imaging-related factors that predict progression to diabetes in children with pancreatitis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatitis, Diabetes Mellitus
Keywords
MRI

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Participants will be prospectively recruited to one or more of four prospective imaging aims (Aims 1-4). All participants who enroll in any imaging Aim will have their images used for Aim 5 (image analysis aim) which will also include a retrospective component.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
195 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Imaging markers of exocrine and endocrine insufficiency
Arm Type
Experimental
Arm Description
We will prospectively enroll 85 participants; 40 with known or suspected EPI and 45 controls (no known organic gastrointestinal pathology and no history of pancreatic disease) in this aim. Participants will be undergoing clinically-indicated endoscopy and will have endoscopic pancreatic function tests (ePFTs) collected for research during the clinically-indicated endoscopy examination. A research blood draw and a research stool collection will also be collected from all participants. Participants will undergo a research MRI examination with administration of intravenous secretin within 2 weeks of their clinical endoscopy but no sooner than 2 hours before or after endoscopy.
Arm Title
Imaging markers of diabetes and prediction of progression to diabetes
Arm Type
Experimental
Arm Description
We will prospectively enroll 30 participants; 10 with a single episode of acute pancreatitis, 10 with acute recurrent pancreatitis, and 10 with pancreatitis-related diabetes in this aim. Participants will undergo a research MRI examination. Participants will also undergo a research blood draw for laboratory analysis and to enable gene sequencing for gene mutations associated with heritable pancreatitis. We will assess the association between identified gene variants and the presence of diabetes and will construct models based on identified variants to predict progression to diabetes.
Arm Title
Imaging stratification of stages of pancreatitis
Arm Type
Experimental
Arm Description
We will prospectively enroll 60 participants; 15 healthy controls, 15 participants with a single episode of acute pancreatitis, 15 participants with acute recurrent pancreatitis, and 15 participants with chronic pancreatitis. A research blood draw and a research stool collection will be collected from all participants. Participants will undergo a research MRI examination with administration of intravenous secretin.
Arm Title
Imaging reproducibility
Arm Type
Experimental
Arm Description
We will prospectively enroll up to 20 participants enrolled in Aims 1 or 3 (up to 5 controls and 15 patients with pancreatic disease) to undergo repeat research MRI imaging between 24 hours and 14 days after their first research MRI. Participants will undergo a research MRI examination with administration of intravenous secretin, identical to the research MRI performed under Aims 1 or 3. MRI images will be quantitatively analyzed and agreement between the two MRI examinations (1st and repeat MRI) will be assessed.
Arm Title
Automated or semi-automated image analysis
Arm Type
No Intervention
Arm Description
We will use images prospectively collected under Aims 1-3, as well as existing images that had been obtained for clinical care of children with pancreatitis at CCHMC to develop and optimize image processing pipelines for MRI images. Performance of these pipelines will be benchmarked against manual segmentation performed by multiple observers.
Intervention Type
Diagnostic Test
Intervention Name(s)
Research MRI without administration of intravenous secretin
Intervention Description
Participants will undergo a research MRI examination. MRI images will be quantitatively analyzed and will be compared to / used to predict diabetes.
Intervention Type
Diagnostic Test
Intervention Name(s)
Research MRI with administration of intravenous secretin
Intervention Description
Participants will undergo a research MRI examination with intravenous administration of secretin. MRI images will be quantitatively analyzed and will be compared to / used to predict exocrine and endocrine pancreatic insufficiency based on the reference standards of ePFTs or fecal elastase and blood hemoglobin A1c (HbA1c) and fasting glucose, respectively.
Intervention Type
Genetic
Intervention Name(s)
Genetic Sequencing
Intervention Description
Blood will be drawn to enable gene sequencing for gene mutations associated with heritable pancreatitis. We will assess the association between identified gene variants and the presence of diabetes and will construct models based on identified variants to predict progression to diabetes.
Intervention Type
Diagnostic Test
Intervention Name(s)
Blood Tests
Intervention Description
Research blood draw (for markers of pancreatic endocrine insufficiency)
Intervention Type
Diagnostic Test
Intervention Name(s)
Stool Tests
Intervention Description
Research stool collection (for fecal elastase as a marker of exocrine insufficiency)
Intervention Type
Other
Intervention Name(s)
Survey Completion
Intervention Description
Participants will be contacted to complete a survey and their charts will be reviewed annually after research MRI to identify any evidence of subsequent development of pancreatic endocrine insufficiency or progression of pancreatitis. Survey and chart review will occur within +/- 14 days of the anniversary date.
Intervention Type
Diagnostic Test
Intervention Name(s)
Endoscopic pancreatic function tests (ePFTs)
Intervention Description
At least two duodenal fluid aspirates will be collected over 15 minutes following secretin administration. Aspirates will be immediately pH tested and will be submitted for analysis of bicarbonate, enzyme (trypsin, amylase, lipase, chymotrypsin) activity, and total protein.
Intervention Type
Drug
Intervention Name(s)
Secretin
Intervention Description
Participants enrolled in Aim 1, Aim 3, and Aim 4 will receive intravenous secretin at a dose of 0.2 mcg/kg (maximum 16 mcg). Participants in Aim 1 will receive two doses (1 during endoscopy and 1 during MRI). Participants in Aim 3 will receive one dose during MRI. Participants in Aim 4 will receive two doses (1 during each MRI). Secretin for intravenous use is FDA-approved for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of exocrine pancreas dysfunction. Safety and effectiveness of secretin in pediatrics have not been established. However, secretin is routinely used in children at CCHMC at the same dose at which it will be administered for this study.
Primary Outcome Measure Information:
Title
Pancreas volume as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).
Description
2 x 2 table analyses of pancreas volume (categorized as normal vs. abnormal) vs. exocrine function (categorized as normal vs. abnormal)
Time Frame
5 years
Title
Pancreas volume as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).
Description
2 x 2 table analyses of pancreas volume (categorized as normal vs. abnormal) vs. endocrine function (categorized as normal vs. abnormal)
Time Frame
5 years
Title
Pancreas T1 signal as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).
Description
2 x 2 table analyses of pancreas T1 signal (categorized as normal vs. abnormal) vs. exocrine function (categorized as normal vs. abnormal)
Time Frame
5 years
Title
Pancreas T1 signal as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).
Description
2 x 2 table analyses of pancreas T1 signal intensity (categorized as normal vs. abnormal) vs. endocrine function (categorized as normal vs. abnormal)
Time Frame
5 years
Title
Pancreas secreted fluid volume as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).
Description
2 x 2 table analyses of pancreas secreted fluid volume (categorized as normal vs. abnormal) vs. exocrine function (categorized as normal vs. abnormal)
Time Frame
5 years
Title
Pancreas secreted fluid volume as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).
Description
2 x 2 table analyses of pancreas secreted fluid volume (categorized as normal vs. abnormal) vs. endocrine function (categorized as normal vs. abnormal)
Time Frame
5 years
Title
Frequency of genetic mutations in patients progressing to diabetes vs. those not
Description
Frequency of genetic mutations in each study group will be compared using 2x2 tables to identify mutations associated with development of diabetes
Time Frame
5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Aim 1- Patient Group: Inclusion Criteria: Age 5 to <21 years Scheduled for clinically-indicated gastrointestinal endoscopy Clinical diagnosis or suspicion of exocrine pancreatic insufficiency Exclusion Criteria: Complete fatty replacement of pancreas on prior imaging Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Allergy to secretin Pregnancy Control Group: Inclusion Criteria: Age 5 to <21 years Scheduled for clinically-indicated gastrointestinal endoscopy Exclusion Criteria: Sweat chloride >60 mmol/L Clinical diagnosis of gastrointestinal pathology Clinical diagnosis or history of pancreatic disease Complete fatty replacement of pancreas on prior imaging Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Allergy to secretin Pregnancy Aim 2- Acute Pancreatitis Group: Inclusion Criteria: Age 5 to <21 years Clinically documented episode of acute pancreatitis Exclusion Criteria: More than one episode of acute pancreatitis Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Pregnancy Acute Recurrent Pancreatitis Group: Inclusion Criteria: Age 5 to <21 years Clinical diagnosis of acute recurrent pancreatitis Exclusion Criteria: Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Pregnancy Pancreatitis-Related Diabetes Group: Inclusion Criteria: Age 5 to <21 years Clinical diagnosis of pancreatitis-related diabetes Exclusion Criteria: Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Pregnancy Aim 3- Control Group: Inclusion Criteria: • Age 5 to <21 years Exclusion Criteria: Sweat chloride >60 mmol/L Clinical diagnosis of gastrointestinal pathology Clinical diagnosis or history of pancreatic disease, including acute pancreatitis Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Allergy to secretin Pregnancy Acute Pancreatitis Group: Inclusion Criteria: Age 5 to <21 years Clinically documented episode of acute pancreatitis Exclusion Criteria: More than one episode of acute pancreatitis Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Allergy to secretin Pregnancy Acute Recurrent Pancreatitis Group: Inclusion Criteria: Age 5 to <21 years Clinical diagnosis of acute recurrent pancreatitis with no evidence of CP or EPI Exclusion Criteria: Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Allergy to secretin Pregnancy Chronic Pancreatitis Group: Inclusion Criteria: Age 5 to <21 years Clinical diagnosis of chronic pancreatitis Exclusion Criteria: Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Allergy to secretin Pregnancy Aim 4- Inclusion Criteria: Age 5 to <21 years Completed research MRI under Aims 1 or 3 of this study Exclusion Criteria: Failed/unable to complete first research MRI under Aims 1 or 3 Episode of acute pancreatitis since first research MRI Current acute pancreatitis Any gastrointestinal surgery or pancreas intervention (e.g. ERCP) since first research MRI Need for sedation for MRI Contraindication to MRI (implanted metal hardware) Allergy to secretin Pregnancy Aim 5- Inclusion Criteria: • MRI performed at CCHMC Exclusion Criteria: Severe image artifact compromising image quality (judgement of study team) Age >21 years
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew Trout, MD
Organizational Affiliation
Children's Hospital Medical Center, Cincinnati
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cincinnati Children's Hospital Medical Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45229
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Imaging Biomarkers of Pancreatic Function and Disease

We'll reach out to this number within 24 hrs